Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$105.77 USD

105.77
144,952

-2.32 (-2.15%)

Updated Jul 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

by Zacks Equity Research

Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.

Company News for Mar 26, 2024

by Zacks Equity Research

Companies in The News:MASI,CLFAMD,UAL

Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Is Masimo (MASI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.

Masimo (MASI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Masimo (MASI) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 31.58% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Masimo (MASI) This Year?

by Zacks Equity Research

Here is how Masimo (MASI) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.

Masimo (MASI), UCHealth Unite to Improve Care With Telehealth

by Zacks Equity Research

Masimo (MASI) collaborates with UCHealth to boost patient care by combining its latest virtual care technologies with UCHealth's clinical expertise and telehealth innovations.

Earnings Preview: Masimo (MASI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Masimo's (MASI) MightySat Pulse Oximeter Receives FDA Approval

by Zacks Equity Research

Masimo's (MASI) MightySat Medical Pulse Oximeter receives FDA clearance, which makes it the first FDA-approved pulse oximeter to be available OTC.

GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve

by Zacks Equity Research

GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.

If You Invested $1000 in Masimo a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Intuitive Surgical (ISRG) Seeks FDA Nod for Next-Gen da Vinci 5

by Zacks Equity Research

Intuitive Surgical (ISRG) aims to boost its da Vinci portfolio with the addition of its next-generation da Vinci 5 multiport surgical robot.

Intuitive Surgical (ISRG) Q4 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosts procedure sales.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy as Industry Trends Improve

by Urmimala Biswas

The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth. HOLX, MASI and VCYT appear well-poised to brave the challenges.

Can Masimo (MASI) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Masimo (MASI) Just Overtook the 200-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Masimo (MASI) Gains on Favorable Ruling in Apple Watch Dispute

by Zacks Equity Research

Masimo (MASI) rides on the continuation of the import ban on certain models of Apple watches using disputed blood oxygen sensors.

Here's How Much a $1000 Investment in Masimo Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.

What's in Store for Boston Scientific (BSX) in Q4 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.